Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

Abstract Background Currently, there are no available targeted therapy options for non-V600 BRAF mutated tumors. The aim of this study was to investigate the effects of RAF and MEK concurrent inhibition on tumor growth, migration, signaling and apoptosis induction in preclinical models of non-V600 B...

Full description

Bibliographic Details
Main Authors: Eszter Molnár, Dominika Rittler, Marcell Baranyi, Michael Grusch, Walter Berger, Balázs Döme, József Tóvári, Clemens Aigner, József Tímár, Tamás Garay, Balázs Hegedűs
Format: Article
Language:English
Published: BMC 2018-05-01
Series:BMC Cancer
Subjects:
Non-V600 BRAF mutation
Sorafenib
AZ628
Selumetinib
Apoptosis
Proliferation
Online Access:http://link.springer.com/article/10.1186/s12885-018-4455-x

Internet

http://link.springer.com/article/10.1186/s12885-018-4455-x

Similar Items